MyChesCo on MSN1 个月
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock
(NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C cardiogenic shock. This ...
Zacks Small Cap Research on MSN2 个月
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones
Among the various upcoming milestones the company expects to report results from its small Phase 2 cardiogenic shock SCAI ...